Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
44 Management <strong>Report</strong> Konzernlagebericht<br />
Production<br />
Our competence is highlighted by our long-standing experience in manufacturing of products for<br />
medtech and biomedical purposes that require highest safety and quality standards. Due to the optimized<br />
teamwork between the different departments such as purchasing, quality management and production<br />
we are able to manufacture specialised products with short lead times.<br />
The company implemented a number of measures to reduce transit times in order to increase operational<br />
efficiency and reduce stocks.<br />
Enhanced usage of the Microsoft Axapta program within the company’s structure as well as design and<br />
workflow changes for the medical products in particular show a major increase in efficiency and workflow<br />
management.<br />
The company has its key production facilities in Germany, US and Latvia and delivers goods all over the<br />
world from these locations.<br />
All production and quality control facilities meet current standards.<br />
Environmental and Quality Management<br />
<strong>biolitec</strong>’s quality management is annually certified by DQS GmbH (German Society for Certification of<br />
Management Systems) in accordance to DIN EN ISO 13485:2003 and DIN EN ISO 9001:2000 standard. In<br />
accordance with the European Union Directive on medical devices (Annex II of Directive 93/42/EEC)<br />
<strong>biolitec</strong> is entitled to use the CE label for products brought into use within the European Union. The<br />
quality management system of the American subsidiaries complies with the requirements of the US<br />
American Food and Drug Administration (FDA). All further subsidiaries are registered at national authorities<br />
as far as required.<br />
With our innovative medical products, we are committed to people and their health. Therefore, we regularly<br />
evaluate and try to reduce all possible risks associated with our products.<br />
Within the scope of our business activities we consider and comply with all relevant environment protection<br />
directives.<br />
Both production processes and the products of the company do not cause hazard to the environment<br />
directly or indirectly. External inspection authorities regularly audit all production facilities as well as the<br />
laboratories.<br />
Subsidiaries<br />
In the past financial year the founding of subsidiaries in Turkey, Spain and Uzbekistan was prepared.